887579-69-3Relevant articles and documents
A larene/ fragrant mixedsurrounds uncle butanol method for preparing ester compounds
-
Paragraph 0116-0123, (2017/02/02)
The invention discloses a preparation method of an aromatic ring/aromatic heterocycle tert-butyl alcohol ester compound. The preparation method of the aromatic ring/aromatic heterocycle tert-butyl alcohol ester compound comprises the following steps of: firstly, under stirring condition, adding aromatic heterocycle borate compound or aromatic ring boric acid compound and di-tert-butyl dicarbonate ester into a solvent, and then adding a palladium catalyst and a ligand, so that a mixture A is obtained; secondly, heating the mixture A for carrying out reaction, and then cooling to room temperature, so that a mixture B is obtained; thirdly, diluting the mixture B with ethyl acetate, then filtering the diluted mixture B with diatomite, collecting filtrate, concentrating, and carrying out spin drying, so that the aromatic ring/aromatic heterocycle tert-butyl alcohol ester compound is obtained. The preparation method of the aromatic ring/aromatic heterocycle tert-butyl alcohol ester compound has the advantages that alkoxycarbonylation reaction on an aromatic heterocycle borate compound or aromatic ring boric acid compound is realized, and the aromatic ring/aromatic heterocycle tert-butyl alcohol ester compound is directly generated; raw materials are non-toxic, inexpensive and available; a catalytic system is low in cost and has good stability and broad applicability; reaction conditions are mild, safety is high, and control is easy; a technology is simple, operation is easy, environmental friendliness is realized, and specificity is strong, so that the preparation method of the aromatic ring/aromatic heterocycle tert-butyl alcohol ester compound is applicable to industrialized production.
A mesoporous organosilica grafted Pd catalyst (MOG-Pd) for efficient base free and phosphine free synthesis of tertiary butyl esters via tertiary-butoxycarbonylation of boronic acid derivatives without using carbon monoxide
Ghosh, Kajari,Molla, Rostam Ali,Iqubal, Md. Asif,Islam
, p. 3540 - 3551 (2015/06/25)
A mesoporous organosilica grafted palladium(ii) catalyst was synthesized and characterized using various spectroscopic techniques. Its catalytic activity was evaluated for the synthesis of tertiary butyl esters via tert-butoxycarbonylation of boronic acid
Preparation of tert-butyl esters via Pd-catalyzed tert-butoxycarbonylation of (hetero)aryl boronic acid derivatives
Wu, Yusheng,Li, Xinjian,Zou, Dapeng,Zhu, Helong,Wang, Yaping,Li, Jingya,Wu, Yangjie
supporting information, p. 1836 - 1839 (2014/05/06)
A novel protocol to synthesize tert-butyl esters from boronic acids or boronic acid pinacol esters and di-t-butyl dicarbonate has been successfully achieved. The cross-coupling reactions can produce up to 94% yields by using palladium acetate and triphenylphosphine as catalyst system, dioxane as a solvent. Moreover, a wide range of substrates including benzenes, pyridines, and quinolines boronic acids or boronic acid pinacol esters can fit with this system as well.
Discovery of novel series of 6-benzyl substituted 4-aminocarbonyl-1,4- diazepane-2,5-diones as human chymase inhibitors using structure-based drug design
Tanaka, Taisaku,Sugawara, Hajime,Maruoka, Hiroshi,Imajo, Seiichi,Muto, Tsuyoshi
, p. 4233 - 4249 (2013/07/27)
A novel series of 6-benzyl substituted 4-aminocarbonyl-1,4-diazepane-2,5- diones were explored as human chymase inhibitors using structure-based drug design according to the X-ray cocrystal structure of chymase and compound 1. The optimization focused on
SEVEN-MEMBERED RING COMPOUND, PRODUCTION METHOD THEREOF AND PHARMACEUTICAL USE THEREOF
-
Page/Page column 57, (2009/03/07)
A 7-membered heterocyclic compound having the formula (I), or its salt, or a solvate thereof with a chymase inhibitory action and useful for the prevention or treatment of various diseases, in which chymase is involved: a method for producing the same, and a pharmaceutical composition useful for the prevention or treatment of diseases, in which chymase is involved, including the compound of having the formula (I), or its pharmaceutically acceptable salt, or a solvate thereof are provided.
